Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The classics in perspective.

× No keyword cloud information.

8 in total

1. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Authors: Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer
Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682

2. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

Authors: Stephen B Hanauer; Carrie L Wagner; Mohan Bala; Lloyd Mayer; Suzanne Travers; Robert H Diamond; Allan Olson; Warren Bao; Paul Rutgeerts
Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382

3. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682

4. Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245

5. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal: Lancet Date: 2002-05-04 Impact factor: 79.321

6. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Authors: W J Sandborn; S B Hanauer; P Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; R Panaccione; D Wolf; J D Kent; B Bittle; J Li; P F Pollack
Journal: Gut Date: 2007-02-13 Impact factor: 23.059

7. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.

Authors: Marc Lémann; Jean-Yves Mary; Bernard Duclos; Michel Veyrac; Jean-Louis Dupas; Jean Charles Delchier; David Laharie; Jacques Moreau; Guillaume Cadiot; Laurence Picon; Arnaud Bourreille; Iradj Sobahni; Jean-Frederic Colombel
Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682

8. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors: Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal: Gastroenterology Date: 2006-02 Impact factor: 22.682

8 in total

1 in total

1. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.

Authors: Sophie Steeland; Leen Puimège; Roosmarijn E Vandenbroucke; Filip Van Hauwermeiren; Jurgen Haustraete; Nick Devoogdt; Paco Hulpiau; Geert Leroux-Roels; Debby Laukens; Philip Meuleman; Martine De Vos; Claude Libert
Journal: J Biol Chem Date: 2014-12-23 Impact factor: 5.157

1 in total